Sage Therapeutics, Inc. (SAGE)
SAGE moved a median of -0.14% 30 minutes after news, and +0.06% by the close. How SAGE actually reacts to news — the realized, point-in-time move the market made, measured across 951 labeled events over the last three years with zero look-ahead.
SAGE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 911 |
| 30-min | -0.14% | 41% | 912 |
| 60-min | -0.06% | 46% | 912 |
| to close | +0.06% | 50% | 911 |
| Middle 50% of SAGE reactions | -0.89% to +0.59% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 951 |
Half of all Sage Therapeutics, Inc. news events land between -0.89% and +0.59% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SAGE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.16% | 40% | +1.84% |
| Analyst downgrades | 20 | +0.76% | 65% | +0.72% |
| Coverage initiations | 12 | +3.01% | 67% | -3.72% |
| Rating reiterations | 97 | +0.11% | 53% | +0.47% |
| Price-target cuts | 32 | +0.41% | 66% | +0.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how SAGE ranks against every other measured name →
That’s how SAGE usually reacts — get an email when it moves on news →Email me when SAGE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SAGE's baseline. Nothing else.
Recent SAGE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Sage Therapeutics, Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form POSASR Sage Therapeutics, Inc. | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Sage Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Sage Therapeutics, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Sage Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Sage Therapeutics, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Sage Therapeutics Announces Second Quarter 2025 Financial Results | Press release | Business Wire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.06% | -0.22% | |
| SAGE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Sage Therapeutics, Inc. is Fair to Shareholders | Press release | ACCESS Newswire | +0.43% | +0.87% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.05% | -0.11% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.06% | +0.11% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.11% | +0.22% | |
| Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.27% | -0.33% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +1.03% | |
| Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.33% | +1.20% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.43% | +1.20% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.00% | +0.66% | |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. | Press release | PR Newswire | +0.00% | +0.77% | |
| Form 8-K Sage Therapeutics, Inc. For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | -0.11% | |
| SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.23% | -0.11% | |
| Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.23% | -0.11% | |
| Form 8-K Sage Therapeutics, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | -0.11% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.30% | -0.30% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.22% | +0.58% | |
| INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the Firm - SAGE | Press release | ACCESS Newswire | -2.16% | -2.01% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.16% | -2.01% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.77% | +3.83% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.91% | -0.68% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.15% | +2.48% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.30% | -0.61% | |
| Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -1.21% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.07% | +1.14% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +2.05% | +3.36% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.15% | +1.69% | |
| Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.82% | -1.12% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +1.26% | -0.15% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.07% | -1.18% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.41% | -2.69% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.69% | -1.51% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.13% | -1.94% | |
| Form 10-Q Sage Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.93% | -2.80% | |
| Form 8-K Sage Therapeutics, Inc. For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | -2.80% | |
| Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates | Press release | Business Wire | +0.93% | -2.80% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.20% | +1.30% | |
| Form ARS Sage Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.03% | +0.78% | |
| Form DEF 14A Sage Therapeutics, Inc. For: Apr 23 | SEC filing · Form DEF | SEC EDGAR | +1.03% | +0.78% | |
| Form DEFA14A Sage Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.03% | +0.78% | |
| Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -1.22% | +0.95% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.73% | -0.53% | |
| Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 | Press release | Business Wire | +0.14% | +1.62% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SAGE section they belong to.
Where else SAGE is measured.
SAGE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Natera, Inc. (NTRA) | 957 | +0.21% | 57% |
| Antares Pharma, Inc. (ATRS) | 951 | 0.00% | 43% |
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Intellia Therapeutics, Inc. (NTLA) | 948 | -0.24% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sage Therapeutics, Inc.'s median reaction calculated?
Every labeled SAGE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 951 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of SAGE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SAGE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.